Article Text

other Versions

PDF
Audit, research and guideline update
A 4-year prospective evaluation of protocols to improve clinical outcomes for patients with lymphangioleiomyomatosis in a national clinical centre
  1. Janet Bee1,
  2. Rupesh Bhatt1,2,
  3. Ian McCafferty1,2,
  4. Simon R Johnson1,3
  1. 1National Centre for Lymphangioleiomyomatosis, Nottingham University Hospitals NHS Trust, Nottingham, Nottinghamshire, UK
  2. 2Renal Tumour Service, University Hospital Birmingham, Birmingham, West Midlands, UK
  3. 3Division of Respiratory Medicine and Respiratory Research Unit, University of Nottingham, Nottingham, Nottinghamshire, UK
  1. Correspondence to Prof Simon R Johnson, Division of Respiratory Medicine, School of Medicine, University of Nottingham, Nottingham NG7 2UH, UK; simon.johnson{at}nottingham.ac.uk

Abstract

Lymphangioleiomyomatosis (LAM) is a rare multisystem disease. Progressive airflow limitation, pneumothorax and angiomyolipoma-related bleeding are major morbidities. As treatments are available for these complications, we prospectively audited loss of FEV1 (ΔFEV1), pneumothorax and angiomyolipoma bleeding against clinical standards over 4 years at the UK Clinical Centre. ΔFEV1 for these patients is lower than previously reported and rates of pneumothorax and angiomyolipoma haemorrhage are low. This suggests that real-time analysis of clinical data with targeted interventions can reduce morbidity in LAM. These measures could be applied as quality standards to compare the emerging LAM clinical networks worldwide.

  • Rare lung diseases

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.